Evaluation of IFNalpha bioavailability by MxA mRNA in HCV patients.
Previously, we have reported the development of a new quantitative-competitive polymerase chain reaction (qc-PCR) method to evaluate interferon-beta (IFNbeta) bioavailability in multiple sclerosis (MS) patients, by measuring mRNA of mixovirus resistance protein A (MxA). Here we show that our assay is also able to assess IFNalpha bioavailability in hepatitis C virus (HCV) patients treated with different IFNalpha regimens. Indeed, our method was able to detect a slight constitutive expression of MxA mRNA in untreated HCV patients (median=70 fgMxA/pgGAPDH) and a significant induction 12 h after the first IFNalpha administration (median=750 fgMxA/pgGAPDH).
Gilli
F
F
Centro Sclerosi Multipla and Laboratorio di Neurobiologia Clinica, Divisione Universitaria di Neurologia, Azienda Ospedaliera S. Luigi, Università di Torino, Regione Gonzole 10, 10043 Orbassano, Italy. NSGLB@TIN.IT
Sala
A
A
Bancone
C
C
Salacone
P
P
Gallo
M
M
Gaia
E
E
Bertolotto
A
A
D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D019204:GTP-Binding Proteins; D006526:Hepatitis C / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D064547:Myxovirus Resistance Proteins; D016133:Polymerase Chain Reaction / Q000379:methods*; D011506:Proteins / Q000032:analysis* / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis*
D000998:Antiviral Agents; D016898:Interferon-alpha; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D011506:Proteins; D012333:RNA, Messenger; D019204:GTP-Binding Proteins